[go: up one dir, main page]

BR0008688A - Antagonistas de il-18 recombinantes utilizáveis no tratamento de distúrbios mediados por il-18 - Google Patents

Antagonistas de il-18 recombinantes utilizáveis no tratamento de distúrbios mediados por il-18

Info

Publication number
BR0008688A
BR0008688A BR0008688-6A BR0008688A BR0008688A BR 0008688 A BR0008688 A BR 0008688A BR 0008688 A BR0008688 A BR 0008688A BR 0008688 A BR0008688 A BR 0008688A
Authority
BR
Brazil
Prior art keywords
treatment
recombinant
mediated disorders
antagonists usable
antagonists
Prior art date
Application number
BR0008688-6A
Other languages
English (en)
Inventor
Yen Sen Ho
Stephen D Holmes
Alexander Harrison Taylor
Sherin S Abdel-Meguid
Original Assignee
Smithkline Beecham Corp
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Smithkline Beecham Plc filed Critical Smithkline Beecham Corp
Publication of BR0008688A publication Critical patent/BR0008688A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"ANTAGONISTAS DE IL-18 RECOMBINANTES UTILIZáVEIS NO TRATAMENTO DE DISTúRBIOS MEDIADOS POR IL-18". mabs de IL-18 quiméricos, humanizados e outros, derivados de mAbs neutralizantes de alta afinidade, composições farmacêuticas contendo os mesmos, métodos de tratamento e diagnósticos são providos.
BR0008688-6A 1999-03-19 2000-03-17 Antagonistas de il-18 recombinantes utilizáveis no tratamento de distúrbios mediados por il-18 BR0008688A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12529999P 1999-03-19 1999-03-19
PCT/US2000/007349 WO2000056771A1 (en) 1999-03-19 2000-03-17 Recombinant il-18 antagonists useful in treatment of il-18 mediated disorders

Publications (1)

Publication Number Publication Date
BR0008688A true BR0008688A (pt) 2002-01-08

Family

ID=22419067

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0008688-6A BR0008688A (pt) 1999-03-19 2000-03-17 Antagonistas de il-18 recombinantes utilizáveis no tratamento de distúrbios mediados por il-18

Country Status (28)

Country Link
US (2) US6706487B1 (pt)
EP (2) EP1961768A1 (pt)
JP (1) JP2002542769A (pt)
KR (1) KR100697120B1 (pt)
CN (1) CN1246335C (pt)
AR (1) AR022952A1 (pt)
AT (1) ATE402191T1 (pt)
AU (1) AU764622B2 (pt)
BR (1) BR0008688A (pt)
CA (1) CA2368965C (pt)
CO (1) CO5470287A1 (pt)
CY (1) CY1108387T1 (pt)
CZ (1) CZ303704B6 (pt)
DE (1) DE60039589D1 (pt)
DK (1) DK1163271T3 (pt)
ES (1) ES2308974T3 (pt)
HK (1) HK1043798B (pt)
HU (1) HU228931B1 (pt)
IL (1) IL144995A0 (pt)
MY (1) MY124219A (pt)
NO (1) NO330391B1 (pt)
NZ (1) NZ513699A (pt)
PL (1) PL202396B1 (pt)
PT (1) PT1163271E (pt)
SI (1) SI1163271T1 (pt)
TR (3) TR200102733T2 (pt)
WO (1) WO2000056771A1 (pt)
ZA (1) ZA200107639B (pt)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5852266A (en) * 1993-07-14 1998-12-22 Hitachi, Ltd. Vacuum circuit breaker as well as vacuum valve and electric contact used in same
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
US7704944B2 (en) 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
AR022952A1 (es) * 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
AU785038B2 (en) * 2000-01-27 2006-08-31 Applied Molecular Evolution, Inc. Ultra high affinity neutralizing antibodies
IL151044A0 (en) * 2000-02-10 2003-04-10 Abbott Lab Antibodies that bind human interleukin-18 and methods of making and using
RS51737B (sr) * 2000-02-21 2011-10-31 Laboratoires Serono Sa. Korišćenje inhibitora il-18
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders
US7179900B2 (en) 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US20040018195A1 (en) * 2002-03-26 2004-01-29 Griswold Don Edgar Diabetes-related immunoglobulin derived proteins, compositions, methods and uses
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
AU2002343870A1 (en) * 2002-11-07 2004-06-07 Kumamoto Technology And Industry Foundation Transgenic mammal carrying ganp and utilization thereof
EP1621616A4 (en) 2003-04-30 2007-07-04 Japan Science & Tech Agency HUMAN ANTI-HUMAN INTERLEUKIN-18 ANTIBODY, FRAGMENT AND METHOD FOR THEIR USE
US20050100965A1 (en) * 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
AU2011224023C1 (en) * 2003-11-12 2013-08-29 Abbvie Inc. IL-18 binding proteins
US7141382B1 (en) 2004-10-12 2006-11-28 Parikh Chirag R Methods for detection of IL-18 as an early marker for diagnosis of acute renal failure and predictor of mortality
MY144906A (en) 2005-10-21 2011-11-30 Novartis Ag Human antibodies against il13 and therapeutic uses
GB0610438D0 (en) * 2006-05-25 2006-07-05 Glaxo Group Ltd Immunoglobulins
PE20080262A1 (es) 2006-05-25 2008-04-30 Glaxo Group Ltd Anticuerpo humanizado contra interleuquina-18
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
PT2238166E (pt) 2007-10-05 2014-02-11 Genentech Inc Utilização do anticorpo anti-amilóide beta em doenças oculares
JPWO2009051220A1 (ja) * 2007-10-19 2011-03-03 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
US20100291071A1 (en) * 2008-08-01 2010-11-18 Immunas Pharma, Inc. Antibody Specific Binding to A-Beta Oligomer and the Use
WO2009099176A1 (ja) * 2008-02-08 2009-08-13 Immunas Pharma, Inc. Aβオリゴマーに特異的に結合する抗体およびその利用
US20110189093A1 (en) * 2008-04-14 2011-08-04 Proscan Rx Pharma Prostate specific membrane antigen antibodies and antigen binding fragments
US9085614B2 (en) 2008-08-01 2015-07-21 Immunas Pharma, Inc. Antibodies that specifically bind to Aβ oligomers and uses thereof
JP2012500242A (ja) * 2008-08-18 2012-01-05 グラクソ グループ リミテッド Ｉｌ−１８アンタゴニストを用いる自己免疫疾患の治療
WO2010040736A2 (en) * 2008-10-07 2010-04-15 Ablynx Nv Amino acid sequences directed against il18 and/or the il-18 receptor and polypeptides comprising the same for the treatment of diseases and/or disorders associated with il-18 mediated signaling
US8168165B2 (en) * 2008-12-23 2012-05-01 Abbott Laboratories Alkylated interleukin-18 compositions
DK2419447T3 (en) 2009-04-17 2017-09-25 Immunas Pharma Inc ANTIBODIES THAT SPECIFICALLY BIND TO A BETA OLIGOMER AND USE THEREOF
EP2377583A1 (en) * 2009-06-30 2011-10-19 Gosen Co., Ltd. Racket string, method for manufacturing same, and racket strung with same
DK2462162T3 (en) 2009-08-06 2017-01-16 Immunas Pharma Inc Antibodies that specifically bind to A-beta oligomers and their use
ES2624835T3 (es) 2009-08-06 2017-07-17 Immunas Pharma, Inc. Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos
TWI465250B (zh) 2009-08-29 2014-12-21 Abbvie Inc 治療用之ｄｌｌ４結合蛋白質
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
EA201290630A1 (ru) * 2010-02-09 2013-03-29 Глаксо Груп Лимитед Лечение расстройства обмена веществ
US9011861B2 (en) 2010-02-25 2015-04-21 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
EP2542582A4 (en) * 2010-03-02 2013-12-04 Abbvie Inc THERAPEUTIC PROTEINS LINKING TO DLL4
US20130109107A1 (en) * 2010-05-25 2013-05-02 The Regents Of The University Of Colorado Diagnosis and treatment of autoimmune disease
MX341369B (es) 2010-07-30 2016-08-17 Genentech Inc * Anticuerpo anti-beta-amiloide humanizado seguro y funcional.
RU2013133846A (ru) 2010-12-20 2015-01-27 Медиммьюн Лимитед Антитела против il-18 и их применение
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
US10570199B2 (en) 2012-11-21 2020-02-25 Km Biologics Co., Ltd. Human antibody against IL-18
JP7274259B2 (ja) * 2015-03-05 2023-05-16 エイビー２ バイオ ソシエテアノニム 炎症性疾患におけるｉｌ－１８結合タンパク質（ｉｌ－１８ｂｐ）および抗体
JP2023530489A (ja) * 2020-06-18 2023-07-18 ネクストキュア インコーポレイテッド Ｆｌｒｔ３媒介性シグナル伝達を調節するための組成物及び方法
WO2023286694A1 (ja) 2021-07-13 2023-01-19 国立大学法人東海国立大学機構 炎症性腸疾患を治療するための医薬組成物
WO2024261470A1 (en) 2023-06-20 2024-12-26 Apollo Ap43 Limited Anti-il-18 antibody therapy for treating atopic dermatitis
CN117986360B (zh) * 2024-02-01 2024-08-27 生物岛实验室 Il18蛋白的特异性抗体及其制备方法与应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
EP0528767B1 (en) * 1991-08-21 2000-01-12 Novartis AG Antibody derivatives
GB9125979D0 (en) * 1991-12-06 1992-02-05 Wellcome Found Antibody
TW464656B (en) 1994-11-15 2001-11-21 Hayashibara Biochem Lab Interferon-gamma production inducing polypeptide monoclonal antibody, and agent for interferon-gamma susceptive disease
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
FR2767697B1 (fr) 1997-09-01 2000-05-05 Boots Co Plc Composition dermatologique permettant d'eviter l'apparition de symptomes d'hypersensibilite et d'intolerance cutanee
CA2276216A1 (en) 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
AR022952A1 (es) * 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL

Also Published As

Publication number Publication date
PL202396B1 (pl) 2009-06-30
EP1163271B1 (en) 2008-07-23
CA2368965C (en) 2010-05-18
EP1961768A1 (en) 2008-08-27
AR022952A1 (es) 2002-09-04
TR200102733T2 (tr) 2002-04-22
DE60039589D1 (de) 2008-09-04
ES2308974T3 (es) 2008-12-16
WO2000056771A1 (en) 2000-09-28
NZ513699A (en) 2004-02-27
DK1163271T3 (da) 2008-11-10
HK1043798A1 (en) 2002-09-27
KR20020008130A (ko) 2002-01-29
HK1043798B (en) 2009-04-09
MY124219A (en) 2006-06-30
CA2368965A1 (en) 2000-09-28
US6706487B1 (en) 2004-03-16
CZ303704B6 (cs) 2013-03-27
CN1246335C (zh) 2006-03-22
CO5470287A1 (es) 2004-12-30
JP2002542769A (ja) 2002-12-17
TR200202254T2 (tr) 2002-12-23
ATE402191T1 (de) 2008-08-15
HUP0200502A2 (en) 2002-06-29
ZA200107639B (en) 2002-09-17
KR100697120B1 (ko) 2007-03-20
HUP0200502A3 (en) 2003-12-29
EP1163271A4 (en) 2003-04-09
NO20014524L (no) 2001-11-14
IL144995A0 (en) 2002-06-30
TR200202253T2 (tr) 2002-12-23
AU764622B2 (en) 2003-08-28
CN1352650A (zh) 2002-06-05
CY1108387T1 (el) 2014-02-12
PL350460A1 (en) 2002-12-16
NO330391B1 (no) 2011-04-04
AU3901600A (en) 2000-10-09
PT1163271E (pt) 2008-09-16
SI1163271T1 (sl) 2008-10-31
HU228931B1 (en) 2013-06-28
NO20014524D0 (no) 2001-09-18
US20040141964A1 (en) 2004-07-22
CZ20013362A3 (cs) 2002-03-13
EP1163271A1 (en) 2001-12-19

Similar Documents

Publication Publication Date Title
BR0008688A (pt) Antagonistas de il-18 recombinantes utilizáveis no tratamento de distúrbios mediados por il-18
IL148079A0 (en) Human ctla-4 antibodies and compositions containing the same
DE60028970D1 (de) An her2 bindende peptidverbindungen
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
ID26984A (id) Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
BR9510499B1 (pt) antagonistas de il-5 recombinantes úteis no tratamento de distúrbios mediados por il-5.
DE69728585D1 (de) Mittel gegen Juckreiz
DE69934515D1 (de) Humanisierte monoklonale integrin antikörper
YU13301A (sh) Muskarinski agonisti i antagonisti
EA200201138A1 (ru) Пептид, модулирующий рецептор тромбопоэтина
WO2003010291A3 (en) Treatment of immune disorders and b cell disorders
ATE199321T1 (de) Anti idiotypische antikörper gegen gonococcen und diese verwendende verfahren und zusammensetzungen.
MX9101958A (es) Inhibidores de acat de urea de aminosulfonilo
EP1401496A4 (en) COMPOSITIONS AND METHODS FOR TREATING HYPERIMMUNE REACTIONS IN THE EYE
IL154522A0 (en) IgE RECEPTOR ANTAGONISTS
NZ515382A (en) OX2 receptor homologs
WO2001040465A3 (en) Compositions and methods for the treatment of immune related diseases
WO2004043397A3 (en) Compositions and methods for the treatment of rheumatoid arthritis
WO2001066709A3 (en) Sphingomyelinase enzymes and uses relating thereto
WO2003087841A3 (en) An ephrin-b receptor protein involved in carcinoma
WO2001066740A3 (en) Compositions and methods for the treatment of immune related diseases
WO2002022658A3 (en) Muteins of the cgrp 1-7 peptide fragment and use thereof as nicotinic neuronal receptor enhancers
WO2001016319A3 (en) Compositions and methods for the treatment of immune related diseases
WO2002092625A3 (en) Moraxella(branhamella) catarrhalis antigens
MXPA01009174A (es) Antagonistas de endotelina novedosos derivados de piridazina.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A E 9A ANUIDADES

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2003 DE 26/05/2009, ITEM 8.6, POR TER SIDO INDEVIDO.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 NA RPI2003 DE 26/05/2009.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.11 DA RPI 2063 DE 20/07/2010.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: SMITHKLINE BEECHAM PLC (GB) , GLAXOSMITHKLINE LLC

Free format text: NOME ALTERADO DE: SMITHKLINE BEECHAM CORPORATION

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O C/C 13, 24 E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.